ISSN 2664-4142 (Print) & ISSN 2664-6749 (Online)
South Asian Research Journal of Pharmaceutical Sciences
Abbreviated Key Title: South Asian Res J Pharm Sci

| Volume-3 | Issue-6 | Nov-Dec- 2021 | **DOI: 10.36346/sarjps.2021.v03i06.001**

Review Article

Clinical Applications of N-Acetylcysteine (NAC): A Review

Navneet Kumar Verma[1*], Asheesh Kumar Singh[1], Vikas Yadav[1], Ankur Yadav[1], Shiwani Jaiswal[1]

[1]Buddha Institute of Pharmacy, GIDA, Gorakhpur, UP, India

***Corresponding Author**
Navneet Kumar Verma

Article History
Received: 17.09.2021
Accepted: 26.10.2021
Published: 11.11.2021

Abstract: It has been used as a drug since the 1960s and is listed on the World Health Organization (WHO) Model List of Essential Medicines as an antidote in poisonings. There are numerous other uses or proposed uses in medicine that are still in preclinical and clinical investigations. NAC is also used in food supplements and cosmetics. It is often used to treat an overdose of the L-amino acid molecule, which is acylated to N-acetylserotonin. Several scientific studies show that supplementation of N-acetylenene improves clinical trials show that it may help to stop exacerbation of COPD and delay or slow down the onset of contrast-induced kidney problems and help with the management of pulmonary fibrosis until it is diagnosed, as well. N-Cysteine can be used to treat H. pylori and H. pylori-align prevention in cancer treatment in patients receiving gentamicin adenoids for the prevention of hearing loss due to gentamicin dopamine administration in patients doing dialysis.

Keywords: L-amino acid molecule, N-acetylserotonin, COPD, N-acetylénene.

INTRODUCTION

N-acetylcysteine (also known as N-acetyl-cysteine, NAC) is a precursor to the amino acid L-cysteine and consequently the antioxidant glutathione (GSH). It is commonly believed to be an antidote for acetaminophen toxicity but has shown to have a few specific uses as well. Due to their ability to stimulate antioxidant and nitric oxide and nitric oxide processes in the body while exposed to radiation, bacteria, radioactive substances, and inflammation, these medicinals may help to increase the protection against them. Increased N-acetylation of glutathione was shown to be beneficial to the body's primary antioxidant enzymes [1, 2]. Glutathione supplementation is needed to deal with a wide range of foreign substances that include xeno-estrogens (chemicals that are not present in living systems), peroxide, and molecules containing free radicals (also known as oxygen radicals). The power of the original can be high, but the volume of the expanded has a dramatic effect on the cells. Three intracellular amino acid tripeptide vitamins include glutathione, taurine, and glutathione synthase (glutamate, glycine, and cysteine) [3]. There are significant shifts in the abundance of cysteine that occur as oxidant stress occurs. If the reduction of cysteine levels occurs, glutathione production is likely to be limited when under certain conditions of increased oxidative stress. It is in the same category of emphysema, which decreases or stops the development of persistent inflammation (i.e. inflammatory disorder, such as COPD) and prevention or treatment for, inhibits emphysema. Its mechanism of action includes acting as a vasodilator by stimulating nitric oxide production and activation and even being an antioxidant. If you have contrast-induced nephropathy, you must expand, and if you are using nitrates, you must dilate [4].

COPD

COPD was shown to have an amino acid supplementation benefit of N-acetylation, which suggested that patients taking treatment over two months have seen significant improvements in three clinical indicators: about visibility, such as a substantial decrease in sputum volume, cough frequency, and patient comfort in 82%, 74%, and 71% (in open-label trials), respectively Within two or three months of therapy, testing, patients have notable changes in breath sounds, cyanosis, and other cardiovascular problems, as well as other medical issues resolved. Five dyspnea were reduced in the number of people requiring one year and two years after treatment was contrasted with those that had no reduction in forced expiratory volume, with N-sulfonium (N-Acetylcysteine, with the placebo and the findings of reduced the number of subjects requiring 1- and 2-year ventilation therapy with N-sulphone in respiratory outcomes

(FEV1) [5, 6]. This specific impact was evident on those in the age range of fifty years. Just in the N-acetylacetylcysteenamidine nitrogen, consumers had an annual rate of loss of lung illness nearly 50% lower than usual (an annual decrease of FEV1 of 30 mL versus 54 mL in the control group). 6 N-acetyl citrulline was evaluated for the possibility of reducing the development of emphysema. The result of a meta-analysis of 11 double-blind, placebo-controlled trials that utilised the best available data (by my choosing) 39 test parameters showed statistical solid evidence of significance in showing a measurable N Acetyl group difference [7]. This set of double-blind clinical trials has included 2,011 cases —956 of analysable data—and 1,015 patients that received none. The number was on a 5.8 for one patient to help deter an exacerbation. Registrations of slight increases in the FEV1 levels were noted. Generally, the prevalence of the side effects is equivalent to the placebo group, with just over 500 needed to have caused medical complications in the 1987 placebo study. Influential research found that there to be no link between N-acetyl succinate and the primary endpoints. Eight thousand five hundred twenty-six patients were selected from the population of 519 COPD sufferers solid statistical and treated for three years by an additional when receiving either 600 mg N-Cyste or a placebo. while the overall primary endpoints of FEV1 value and FEV1 depletion were not substantially different, inhaled steroids enhanced the FEV1 retention for certain patients rather than for others, some who were prescribed N-acetylcysteine (GII: customers received N-acetylcysteine, while all other subjects received N-acet, TNS patients experienced an exacerbation Contrast-induced nephropathy, Contrast-induced nephrotoxicity This value is ten million times more than the number of radiologic contrast substance procedures performed in the United States annually. Nine the volume of the creatinine metabolic breakdown product between about 2 mg/dL to 20% below the normal limit is seen in patients, whereas the ratio of the amount of creatinine in blood to the normal amount is in the higher range at 5 mg/dL (180 µmol/L) to 30 mg/dL (320 µmol/L). Patients with a history of diabetes and patients whose creatinine level is at or beyond 2 mg per L (180 µmol per L) are at a greater risk [8-10]. As a result, contrast-induced nephropathy is more prevalent and affects patients over a longer period post-surgery and regardless of the need for post-surgical dialysis [11]. Thus, a very recent study of N-acetylcysteine as contrast-induced nephropathy prophylaxis conducted in a prominent scientific journal resulted in around 15 years ago, resulting in at least in 12 trials and 13 reviews of analyses by the implication that RCTs had been using this time about the year 2000 resulted in more effort than any previous studies [12-15]. Five of the meta-analyses determined that N-Acetylanthranilic is useful in reducing the risk of contrast-induced nephosphægy, and three did not. On the other hand, three of the studies concluded that it was unsuccessful in treating or avoiding dialysis for the various organs on four separate occasions. Inclusive (wide) spread the research findings currently available in the RCTs in the field of clinical studies have too much heterogeneity (i.e., random differences exist) to permit a solid conclusion in the other realm [15]. A new test looked at 354 patients who had suffered an infarction in the anterior wall of the heart [16]. Patients have treated with a placebo-doses of 600 mg every morning for four days or with a daily dose of 1200 mg for two days before and 600 mg at night for eight nights, and in all two and four weeks before angioplasty treatment (1,200-mg bolus intravenously, followed by 1,200 mg orally twice daily for four days). A marked difference in the incidence of contrast-induced nephropathy was seen (N-CiN = 35% vs control; standard-C-CiN = 15%; highly significant) in the patients as compared to the reference-dose (35% less, however, vs the reference dose [.0001]; on the large dose, no difference in the incidence of nephropathy, P.00016% less in the high-ref dose of N-C nephropathy). in comparison; the mortality was low (that is, around 3%) during the whole hospital stay after the occurrence of acute myocardial infarction, along with acute renal failure (that is, kidney failure) that required the use of N-acetylcysteine and mechanical ventilation) as well as the need for a ventilator during the initial period (P = .002) [16]. The only positive survival research on this procedure showed a small advantage. Pharmaceutical management of contrast-induced nephropathy is not in this patient is not given priority because of the results of dichotomous testing. As for N-acetyl succinimide, despite these being seen to be safe and efficient, use still has been shown, use has increased for clinical use [17]. Influenza virus N-acetyl ser/(Expanded)to a)Compared with placebo in an elderly population, N acetyl was shown to be statistically even more effective at reducing the frequency of flu for those who had enrolled in a double-blind, randomised clinical trial for six months. Eighteen the clinical investigators began an active antibody delivery or a dose of N-Cysteine before the influenza A/G (H1N1N1) virus vaccination in 262 people, who were then maintained on the intervention for two years and followed for the rest of the year for a total of four years, starting in 1991 Though the treatment groups in the study of the Hong Kong Flu had equal levels of serotype A/H1N Singapore H1N1N1 virus, patients taking acetyl-L amino acid have less flu-like symptoms (51% of the placebo community compared to 29% of the acetyl-L amino acid group; P = 6.78E In comparison, incidents of clinical influenza among N-cysteine-capped patients are characterised by, on average, as less virulence, less morbidity, pathogenicity, and respiratory distress. The population that was administered the N-acetyl-L-glutamine supplement exhibited significant improvements in its cellular tolerance, which was not the case with the control group that received no treatment [18]. Isocline Idiopathic Pulmonary Fibrosis A study of 155 patients with idiopathicaryopat pulmonary fibrosis that compared participants receiving the supplement to age- and sex-matched controls found that the single-daily intake of N-cysteine (600 mg) led to less decline in lung function as assessed by carbon monoxide-enhancing ability, reported one-inhaling capacity monoxide (9 per cent) in those receiving the supplement. In contrast, participants in the placebo group were (found) in essence three times as much worse off over one year (vital capacity, 9 per cent versus regular 24 per cent) [19]. Also, those patients who obtained N-stearic acid amine, a low-containing type of azathioprine, had fewer problems with bone toxicity from the azathioprine (regardless of whether they received Imuran in addition to the N-acetylene or not) (14% in contrast to 33%

of those given the more abundant S-alkyl ester group) [19]. a. Polycystic ovary syndrome insulin tolerance can be lessened by N-acetyl cysteine. The RCT followed by administering either gave 1,200 mg of N-acetylcysteine (Clomid) or a placebo to women with polycystic ovary syndrome and showed a significant improvement in the chances of becoming pregnant after therapy [20]. Clinically and statistically meaningful changes in ovulation were observed in the population that resulted in the application of N-Acetyl cysteine. To reiterate, these findings have been seen in a separate test as well [21]. Additional indications Inhibiting the onset of symptoms after surgery may be due to N-acetyl acetylcysteine. Amputation has not seen a significant benefit; however, subgroup analysis of patients who had cardiopulmonary bypass has shown a reduction in acute renal failure (P = .06) [22]. Additional research found that N-Acetylsarcosanlolic acid can be used to eliminate oesophagalsolid statistical or help alleviate the possible lung complications of a complication of removal of esophagectomy surgery in 22 patients. [Useful when used] alongside conventional therapy in the eradication of H. pylori infections, N-acetyL Nostra. can also suppress colon polyps, A cysts and are superior to treating these bacterial infections [23-25]. According to f brief preliminary results. Yet, with promising research, treatment with N-acetyl-l-site Acepromazine reduces the chance of gentamicin toxicity in people on hemodialysis patients who are getting it. [26] A broad array of possible side effects and a few harmful reactions in doses of between 1,200 and 1,300 mg twice daily, N-acetylene has few to no side effects. distention, however, certain side effects are uncommon but may involve nausea, vomiting, diarrhoea, and occasional flushing, as well as occasional, mild abdominal pain and constipation [27]. At higher dosages are noted to be frequently effective in the treatment of acetaminophen than those mentioned above, with side effects such as headache, tinnitus, rash, fever, and skin r N, often seen in this is a complicated with a side effect: paresthesia, Caliente, urticarias, and anaphylaxis (pseudoanaphylaxis) [27] care should be exercised in patients who may be taking nitroglycerin- and associated drugs, in which the usage of N-acetyl cysteine has the potential to pose a risk of lowering blood pressure what resources it is supplied with As an over-of-of-the-the-counter substitute, N-acetyl cysteine is used in 500 to 1,000-capsule preparations. The most often used power is 600 mg of this time of year (PureEncapsulations). Act. An intravenous (IV) solution (Acadol) is used for treating acetaminophen poisoning is available. Various N-Nylon Expanders Bottom Line N-Cysteine is convenient, cheap, well-known to cause few or no side effects, and has a clear mechanism of action. Even though the risk/benefit ratio is favourable and has low, doctors may consider using N-acetyl cysteine to help patients who are suffering from idiopathic pulmonary cy to help them with COPD alleviate their symptoms; because N-acetyl cysteine is effective at attenuating the rise in COPD complications, it may be used to help COPD patients who are on dialysis avoid complications; polycystic ovary syndrome women can benefit from it since it has a low likelihood of exposing them to complications due to the use of the laparoscope [28].

NAC as an Anti-Aging Supplement, Effects on Degenerative Processes

NAC can potentially be effective in degenerative processes caused by aging, for instance, in neurodegenerative disorders, neuropathic pain, and stroke [29]. The present findings from animal studies support a neuroprotective role of NAC in controlling age-related neurological disorders [30]. For instance, NAC protects against Cd-induced neuronal apoptosis in mouse brain partially by inhibiting ROS-dependent activation of Akt/mTOR pathway. The findings highlight that NAC may be exploited for prevention and treatment of Cd-induced neurodegenerative diseases [31]. Animal model results support the possibility that NAC could be explored in clinical trials for amyotrophic lateral sclerosis disease [32], as well as Alzheimer's disease [33] and mild cognitive impairment [34]. Further animal studies have shown that it delays age-associated memory impairment and improves aging-related myocardial dysfunctions. Since oxidative stress plays a prominent role in the modulation of neuropathic pain, NAC could be a potential candidate for its alleviation [35]. Furthermore, NAC could be used in endotoxemic states to prevent oxidative damage [36]. This warrants some caution, because NAC was associated with cardiac performance depression in a human trial [37]. NAC has a potential to improve immune function among the elderly [38]. A recent meta-analysis has also revealed a positive effect of NAC on human cognition, in healthy as well as mentally ill individuals [39]. NAC may be helpful in chronic fatigue syndrome [40]. Topical NAC may prevent UV-associated photoaging of the skin [41]. The synthesis of GSH is decreased in the elderly, which increases oxidative stress, itself a propagator of aging. This effect can be reversed with dietary supplementation [42]. Many medical conditions with beneficial role of NAC that are listed above are aging-associated. Based on these facts and the known molecular mechanisms of NAC as an antioxidant, we can hypothesize that it has potential as an anti-aging supplement. The dosage and timing of administration are even more of a concern here than in the case of sports supplementation, since ameliorating the effects of aging would require its long-term use. This would also raise the question of potential long-term side effects, which remains to be answered.

CONCLUSION

It is often used to treat an overdose of the L-amino acid molecule, which is acylated to N-acetylser serotonin. Studies show it may help to stop exacerbation of COPD and delay or slow down the onset of contrast-induced kidney problems. COPD was shown to have an amino acid supplementation benefit of N-acetylation. Patients taking treatment over two months have seen significant improvements in three clinical indicators. Within two or three months of therapy, testing, patients have notable changes in breath sounds, cyanosis, and other cardiovascular problems, as well as other medical issues resolved. Contrast-induced nephropathy is more prevalent and affects patients over a longer period post-surgery and regardless of the need for post-surgical dialysis. Five studies determined that N-Acetylanthranilic is useful in

reducing the risk. Three studies concluded that it was unsuccessful in treating or avoiding dialysis for the various organs on four separate occasions. Patients taking acetyl-L amino acid have less flu-like symptoms than those who took a placebo. Study of 155 patients with idiopathicaryopat pulmonary fibrosis found that N-cysteine led to less decline in lung function. N-Acetylsarcosanlolic acid can be used to eliminate oesophagalsolid statistical or help alleviate the possible lung complications of a complication of removal of esophagectomy surgery. Treatment with N-acetyl-l-site Acepromazine reduces the chance of gentamicin toxicity in people on hemodialysis patients who are getting it. High dosages are noted to be frequently effective in the treatment of acetaminophen. N-Cysteine is convenient, cheap, well-known to cause few or no side effects, and has a clear mechanism of action. N-acetylcysteine is a novel adjunctive treatment for polycystic ovary syndrome patients with polycytic hemangioma. It is also a useful treatment for patients with pulmonary fibrosis and for those suffering from acute renal failure after coronary angiography. The study was published in the journal of the European Journal of Respiratory Respirational Medicine. The authors conclude that acetylcy Steine is an effective treatment for the treatment of chronic obstructive pulmonary disease (COPD) N-Acetyl cysteine has been used to treat polycystic ovary syndrome and to prevent acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery. It has also been found to reduce the proliferative index in the colon of patients with previous adenomatous colonic polyps.

REFERENCES

1. Chiew, A. L., Gluud, C., Brok, J., & Buckley, N. A. (2018). Interventions for paracetamol (acetaminophen) overdose. *Cochrane Database of Systematic Reviews*, (2), CD003328.
2. Dekhuijzen, P. N. R. (2004). Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. *European Respiratory Journal*, *23*(4), 629-636.
3. Dickinson, D. A., Moellering, D. R., Iles, K. E., Patel, R. P., Levonen, A. L., Wigley, A., ... & Forman, H. J. (2003). Cytoprotection against oxidative stress and the regulation of glutathione synthesis. *Biol Chem*, 384(4), 527-537.
4. Ardissino, D., Merlini, P. A., Savonitto, S., Demicheli, G., Zanini, P., Bertocchi, F., ... & Mussini, A. (1997). Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. *Journal of the American College of Cardiology*, *29*(5), 941-947.
5. Tattersall, A. B., Bridgman, K. M., & Huitson, A. (1983). Acetylcysteine (Fabrol) in chronic bronchitis—a study in general practice. *Journal of international medical research*, *11*(5), 279-284.
6. Lundback, B., Linstrom, M., Andersson, S., Nystrom, L., Rosenhall, L., & Stjernberg, N. (1992). Possible effect of acetylcysteine on lung function. *Eur. J. Respir*, *5*(Suppl 15), 289S.
7. Stey, C., Steurer, J., Bachmann, S., Medici, T. C., & Tramer, M. R. (2000). The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. *European Respiratory Journal*, *16*(2), 253-262.
8. Decramer, M., Rutten-van Mölken, M., Dekhuijzen, P. R., Troosters, T., van Herwaarden, C., Pellegrino, R., ... & Ardia, A. (2005). Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. *The Lancet*, *365*(9470), 1552-1560.
9. Liu, R., Nair, D., Ix, J., Moore, D. H., & Bent, S. (2005). N-acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. *Journal of general internal medicine*, *20*(2), 193-200.
10. Rihal, C. S., Textor, S. C., Grill, D. E., Berger, P. B., Ting, H. H., Best, P. J., ... & Holmes Jr, D. R. (2002). Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *circulation*, *105*(19), 2259-2264.
11. Tepel, M., Van Der Giet, M., Schwarzfeld, C., Laufer, U., Liermann, D., & Zidek, W. (2000). Prevention of radiographic-contrast-agent–induced reductions in renal function by acetylcysteine. *New England Journal of Medicine*, *343*(3), 180-184.
12. Bagshaw, S. M., McAlister, F. A., Manns, B. J., & Ghali, W. A. (2006). Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. *Archives of internal medicine*, *166*(2), 161-166.
13. Zagler, A., Azadpour, M., Mercado, C., & Hennekens, C. H. (2006). N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. *American heart journal*, *151*(1), 140-145.
14. Seyon, R. A., Jensen, L. A., Ferguson, I. A., & Williams, R. G. (2007). Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention. *Heart & Lung*, *36*(3), 195-204.
15. Gonzales, D. A., Norsworthy, K. J., Kern, S. J., Banks, S., Sieving, P. C., Star, R. A., ... & Danner, R. L. (2007). A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. *BMC medicine*, *5*(1), 1-13.
16. Marenzi, G., Assanelli, E., Marana, I., Lauri, G., Campodonico, J., Grazi, M., ... & Bartorelli, A. L. (2006). N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. *New England Journal of Medicine*, *354*(26), 2773-2782.
17. Van Praet, J. T., & De Vriese, A. S. (2007). Prevention of contrast-induced nephropathy: a critical review. *Current opinion in nephrology and hypertension*, *16*(4), 336-347.
18. De Flora, S., Grassi, C., & Carati, L. (1997). Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. *European Respiratory Journal*, *10*(7), 1535-1541.
19. Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., ... & Montanari, M. (2005). High-dose acetylcysteine in idiopathic pulmonary fibrosis. *New England Journal of Medicine*, *353*(21), 2229-2242.

20. Rizk, A. Y., Bedaiwy, M. A., & Al-Inany, H. G. (2005). N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate–resistant patients with polycystic ovary syndrome. *Fertility and sterility*, *83*(2), 367-370.
21. Badawy, A., State, O., & Abdelgawad, S. (2007). N-Acetyl cysteine and clomiphene citrate to induce ovulation in polycystic ovary syndrome: a crossover trial. *Acta Obstet Gynecol Scand*, 86(2), 218-222.
22. Sisillo, E., Ceriani, R., Bortone, F., Juliano, G., Salvi, L., Veglia, F., ... & Marenzi, G. (2008). N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. *Critical care medicine*, *36*(1), 81-86.
23. Zingg, U., Hofer, C. K., Seifert, B., Metzger, U., & Zollinger, A. (2007). High dose N-acetylcysteine to prevent pulmonary complications in partial or total transthoracic esophagectomy: results of a prospective observational study. *Diseases of the Esophagus*, *20*(5), 399-405.
24. Estensen, R. D., Levy, M., Klopp, S. J., Galbraith, A. R., Mandel, J. S., Blomquist, J. A., & Wattenberg, L. W. (1999). N-acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps. *Cancer letters*, *147*(1-2), 109-114.
25. Gurbuz, A. K., Ozel, A. M., Ozturk, R., Yildirim, S., Yazgan, Y., & Demirturk, L. (2005). Effect of N-acetyl cysteine on Helicobacter pylori. *Southern medical journal*, *98*(11), 1095-1098.
26. Feldman, L., Efrati, S., Eviatar, E., Abramsohn, R., Yarovoy, I., Gersch, E., ... & Weissgarten, J. (2007). Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. *Kidney international*, *72*(3), 359-363.
27. Atkuri, K. R., Mantovani, J. J., Herzenberg, L. A., & Herzenberg, L. A. (2007). N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency. *Current opinion in pharmacology*, *7*(4), 355-359.
28. Hendler, S. S., ed. (2001). PDR for Nutritional Supplements. 1st ed. Montvale, N. J.: Medical Economics; 11-14.
29. Tardiolo, G., Bramanti, P., & Mazzon, E. (2018). Overview on the effects of N-acetylcysteine in neurodegenerative diseases. *Molecules*, *23*(12), 3305.
30. Garg, G., Singh, S., Singh, A. K., & Rizvi, S. I. (2018). N-acetyl-L-cysteine attenuates oxidative damage and neurodegeneration in rat brain during aging. *Canadian journal of physiology and pharmacology*, *96*(12), 1189-1196.
31. Chen, S., Ren, Q., Zhang, J., Ye, Y., Zhang, Z., Xu, Y., ... & Chen, L. (2014). N-acetyl-L-cysteine protects against cadmium-induced neuronal apoptosis by inhibiting ROS-dependent activation of A kt/m TOR pathway in mouse brain. *Neuropathology and applied neurobiology*, *40*(6), 759-777.
32. Andreassen, O. A., Dedeoglu, A., Klivenyi, P., Beal, M. F., & Bush, A. I. (2000). N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. *Neuroreport*, *11*(11), 2491-2493.
33. B Pocernich, C., LB Lange, M., Sultana, R., & A Butterfield, D. (2011). Nutritional approaches to modulate oxidative stress in Alzheimer's disease. *Current Alzheimer Research*, *8*(5), 452-469.
34. Huang, Q., Aluise, C. D., Joshi, G., Sultana, R., St. Clair, D. K., Markesbery, W. R., & Butterfield, D. A. (2010). Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment. *Journal of neuroscience research*, *88*(12), 2618-2629.
35. Naik, A. K., Tandan, S. K., Dudhgaonkar, S. P., Jadhav, S. H., Kataria, M., Prakash, V. R., & Kumar, D. (2006). Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N-acetyl-L-cysteine in rats. *European Journal of Pain*, *10*(7), 573-579.
36. Zhang, H., Spapen, H., Nguyen, D. N., Rogiers, P., Bakker, J., & Vincent, J. L. (1995). Effects of N-acetyl-L-cysteine on regional blood flow during endotoxic shock. *European surgical research*, *27*(5), 292-300.
37. Peake, S. L., Moran, J. L., & Leppard, P. I. (1996). N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock. *Critical care medicine*, *24*(8), 1302-1310.
38. Arranz, L., Fernández, C., Rodríguez, A., Ribera, J. M., & De la Fuente, M. (2008). The glutathione precursor N-acetylcysteine improves immune function in postmenopausal women. *Free Radical Biology and Medicine*, *45*(9), 1252-1262.
39. Skvarc, D. R., Dean, O. M., Byrne, L. K., Gray, L., Lane, S., Lewis, M., ... & Marriott, A. (2017). The effect of N-acetylcysteine (NAC) on human cognition–A systematic review. *Neuroscience & Biobehavioral Reviews*, *78*, 44-56.
40. Logan, A. C., & Wong, C. (2001). Chronic fatigue syndrome: oxidative stress and dietary modifications. *Alternative Medicine Review*, *6*(5), 450-460.
41. Kang, S., Chung, J. H., Lee, J. H., Fisher, G. J., Wan, Y. S., Duell, E. A., & Voorhees, J. J. (2003). Topical N-acetyl cysteine and genistein prevent ultraviolet-light-induced signaling that leads to photoaging in human skin in vivo. *Journal of Investigative Dermatology*, *120*(5), 835-841.
42. Sekhar, R. V., Patel, S. G., Guthikonda, A. P., Reid, M., Balasubramanyam, A., Taffet, G. E., & Jahoor, F. (2011). Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation–. *The American journal of clinical nutrition*, *94*(3), 847-853.

CITATION: Navneet Kumar Verma *et al* (2021). Clinical Applications of N-Acetylcysteine (NAC): A Review. *South Asian Res J Pharm Sci*, *3*(6): 73-77.